10 Minutes
CONTENU
L’oxycodone est un médicament opioïde classifié comme « puissant », comme la morphine. Au cours des dernières années, son usage s’est accru de manière préoccupante à l’échelle mondiale, malgré l’absence de bénéfice pharmacologique distinct par rapport à la morphine.
En revanche, l’oxycodone affiche une influence dopaminergique plus substantielle et prolongée que la morphine, ce qui pourrait être associé à un profil davantage propice à la dépendance. Les données statistiques confirment la hausse des cas d’usage abusif de l’oxycodone, incluant des incidents d’intoxication et de décès.
(1) Kalso E. (2005). Oxycodone. Journal of pain and symptom management, 29(5 Suppl), S47–S56. https://doi.org/10.1016/j.jpainsymman.2005.01.010
(2) Zipursky, J. S., Everett, K., Gomes, T., Paterson, J. M., Li, P., Austin, P. C., Mamdani, M., Ray, J. G., & Juurlink, D. N. (2023). Prescription of oxycodone versus codeine after childbirth and risk of persistent opioid use: a population-based cohort study. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne, 195(29), E973–E983. https://doi.org/10.1503/cmaj.221351
(3) Cheung, C. W., Ching Wong, S. S., Qiu, Q., & Wang, X. (2017). Oral Oxycodone for Acute Postoperative Pain: A Review of Clinical Trials. Pain physician, 20(2S), SE33–SE52. https://pubmed.ncbi.nlm.nih.gov/28226340/
(4) Oxycodone and oxycontin. (2001). The Medical letter on drugs and therapeutics, 43(1113), 80–81. https://pubmed.ncbi.nlm.nih.gov/11581580/
(5) Anastassopoulos, K. P., Chow, W., Ackerman, S. J., Tapia, C., Benson, C., & Kim, M. S. (2011). Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. Journal of opioid management, 7(3), 203–215. https://doi.org/10.5055/jom.2010.0063
(6) Cherrier, M. M., Amory, J. K., Ersek, M., Risler, L., & Shen, D. D. (2009). Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults. The journal of pain, 10(10), 1038–1050. https://doi.org/10.1016/j.jpain.2009.03.017
(7) Kiyatkin E. A. (2019). Respiratory depression and brain hypoxia induced by opioid drugs: Morphine, oxycodone, heroin, and fentanyl. Neuropharmacology, 151, 219–226. https://doi.org/10.1016/j.neuropharm.2019.02.008
(8) Lugo, R. A., & Kern, S. E. (2004). The pharmacokinetics of oxycodone. Journal of pain & palliative care pharmacotherapy, 18(4), 17–30. https://doi.org/10.1300/j354v18n04_03
(9) Kibaly, C., Alderete, J. A., Liu, S. H., Nasef, H. S., Law, P. Y., Evans, C. J., & Cahill, C. M. (2021). Oxycodone in the Opioid Epidemic: High ‘Liking’, ‘Wanting’, and Abuse Liability. Cellular and molecular neurobiology, 41(5), 899–926. https://doi.org/10.1007/s10571-020-01013-y
(10) Kimbrough, A., Kononoff, J., Simpson, S., Kallupi, M., Sedighim, S., Palomino, K., Conlisk, D., Momper, J. D., de Guglielmo, G., & George, O. (2020). Oxycodone self-administration and withdrawal behaviors in male and female Wistar rats. Psychopharmacology, 237(5), 1545–1555. https://doi.org/10.1007/s00213-020-05479-y